Wellbeing Pharmacies Limited SC332091 false 2025-01-01 2025-12-31 2025-12-31 The principal activity of the company is Retail pharmacist Digita Accounts Production Advanced 6.30.9574.0 true true SC332091 2025-01-01 2025-12-31 SC332091 2025-12-31 SC332091 bus:OrdinaryShareClass1 2025-12-31 SC332091 core:HirePurchaseContracts core:CurrentFinancialInstruments 2025-12-31 SC332091 core:HirePurchaseContracts core:Non-currentFinancialInstruments 2025-12-31 SC332091 core:CurrentFinancialInstruments 2025-12-31 SC332091 core:CurrentFinancialInstruments core:WithinOneYear 2025-12-31 SC332091 core:Non-currentFinancialInstruments 2025-12-31 SC332091 core:Non-currentFinancialInstruments core:AfterOneYear 2025-12-31 SC332091 core:OtherResidualIntangibleAssets 2025-12-31 SC332091 core:CostValuation 2025-12-31 SC332091 core:DisposalsRepaymentsInvestments 2025-12-31 SC332091 core:FurnitureFittingsToolsEquipment 2025-12-31 SC332091 core:LandBuildings 2025-12-31 SC332091 bus:SmallEntities 2025-01-01 2025-12-31 SC332091 bus:AuditExemptWithAccountantsReport 2025-01-01 2025-12-31 SC332091 bus:FilletedAccounts 2025-01-01 2025-12-31 SC332091 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 SC332091 bus:RegisteredOffice 2025-01-01 2025-12-31 SC332091 bus:CompanySecretary2 2025-01-01 2025-12-31 SC332091 bus:Director1 2025-01-01 2025-12-31 SC332091 bus:Director3 2025-01-01 2025-12-31 SC332091 bus:Director4 2025-01-01 2025-12-31 SC332091 bus:OrdinaryShareClass1 2025-01-01 2025-12-31 SC332091 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 SC332091 bus:Agent1 2025-01-01 2025-12-31 SC332091 core:OtherResidualIntangibleAssets 2025-01-01 2025-12-31 SC332091 core:FurnitureFittings 2025-01-01 2025-12-31 SC332091 core:FurnitureFittingsToolsEquipment 2025-01-01 2025-12-31 SC332091 core:LandBuildings 2025-01-01 2025-12-31 SC332091 core:LeaseholdImprovements 2025-01-01 2025-12-31 SC332091 core:MotorVehicles 2025-01-01 2025-12-31 SC332091 core:OfficeEquipment 2025-01-01 2025-12-31 SC332091 core:PlantMachinery 2025-01-01 2025-12-31 SC332091 countries:Scotland 2025-01-01 2025-12-31 SC332091 2024-12-31 SC332091 core:OtherResidualIntangibleAssets 2024-12-31 SC332091 core:CostValuation 2024-12-31 SC332091 core:FurnitureFittingsToolsEquipment 2024-12-31 SC332091 core:LandBuildings 2024-12-31 SC332091 2024-01-01 2024-12-31 SC332091 2024-12-31 SC332091 bus:OrdinaryShareClass1 2024-12-31 SC332091 core:HirePurchaseContracts core:CurrentFinancialInstruments 2024-12-31 SC332091 core:HirePurchaseContracts core:Non-currentFinancialInstruments 2024-12-31 SC332091 core:CurrentFinancialInstruments 2024-12-31 SC332091 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 SC332091 core:Non-currentFinancialInstruments 2024-12-31 SC332091 core:Non-currentFinancialInstruments core:AfterOneYear 2024-12-31 SC332091 core:OtherResidualIntangibleAssets 2024-12-31 SC332091 core:FurnitureFittingsToolsEquipment 2024-12-31 SC332091 core:LandBuildings 2024-12-31 SC332091 bus:OrdinaryShareClass1 2024-01-01 2024-12-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: SC332091

Wellbeing Pharmacies Limited

Annual Report and Unaudited Financial Statements

for the Year Ended 31 December 2025

 

Wellbeing Pharmacies Limited

Contents

Company Information

1

Statement of Directors' Responsibilities

2

Accountants' Report

3

Balance Sheet

4

Notes to the Unaudited Financial Statements

5 to 13

 

Wellbeing Pharmacies Limited

Company Information

Directors

M A Hedley

K A Murphy

F T Gourlay

Company secretary

Mrs J A Hedley

Registered office




Registration number


Principal place of
business

 

31 Townsend Place
Kirkcaldy
Fife
KY1 1HB

SC332091 (Scotland)


Unit 6 Katherine Park
Katherine Street
Kirkcaldy
Fife
KY2 5JY
 

Accountants

Brown, Scott & Main
Chartered Accountants
31 Townsend Place
Kirkcaldy
Fife
KY1 1HB

 

Wellbeing Pharmacies Limited

Statement of Directors' Responsibilities

The directors acknowledge their responsibilities for preparing the Annual Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

select suitable accounting policies and apply them consistently;

make judgements and accounting estimates that are reasonable and prudent;

prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

 

Chartered Accountants' Report to the Board of Directors on the Preparation of the Unaudited Statutory Accounts of
Wellbeing Pharmacies Limited
for the Year Ended 31 December 2025

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Wellbeing Pharmacies Limited for the year ended 31 December 2025 as set out on pages 4 to 13 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of The Institute of Chartered Accountants of Scotland, we are subject to its ethical and other professional requirements which are detailed at www.icas.com/accountspreparationguidance

This report is made solely to you, in accordance with the terms of our engagement. Our work has been undertaken solely to prepare for your approval the financial information of Wellbeing Pharmacies Limited and state those matters that we have agreed to state to you in this report in accordance with the requirements of The Institute of Chartered Accountants of Scotland as detailed at http://www.icas.com/accountspreparationguidance. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and its Board of Directors, as a body, for our work or for this report.

It is your duty to ensure that Wellbeing Pharmacies Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Wellbeing Pharmacies Limited. You consider that Wellbeing Pharmacies Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Wellbeing Pharmacies Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

Brown, Scott & Main
Chartered Accountants
31 Townsend Place
Kirkcaldy
Fife
KY1 1HB

30 June 2026

 

Wellbeing Pharmacies Limited

(Registration number: SC332091)
Balance Sheet as at 31 December 2025

Note

2025
£

2024
£

Fixed assets

 

Intangible assets

6

607,251

645,950

Tangible assets

7

135,529

146,279

Investments

8

187,074

222,299

 

929,854

1,014,528

Current assets

 

Stock

157,459

175,815

Debtors

9

427,367

427,672

Cash at bank and in hand

 

187,495

193,663

 

772,321

797,150

Creditors: Amounts falling due within one year

10

(890,005)

(912,358)

Net current liabilities

 

(117,684)

(115,208)

Total assets less current liabilities

 

812,170

899,320

Creditors: Amounts falling due after more than one year

10

(601,912)

(643,660)

Provisions for liabilities

11

(27,645)

(22,165)

Net assets

 

182,613

233,495

Capital and reserves

 

Called up share capital

13

5,882

5,882

Share premium reserve

18,264

18,264

Retained earnings

158,467

209,349

Shareholders' funds

 

182,613

233,495

For the financial year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 29 June 2026 and signed on its behalf by:
 

.........................................
M A Hedley
Director

 

Wellbeing Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025

1

General information

Wellbeing Pharmacies Limited is a private company, limited by shares, registered in Scotland. The company's registration number and registered office address can be found on the Company Information page.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Basis of preparation

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The presentation currency is sterling.

Group accounts not prepared

The financial statements contain information about Wellbeing Pharmacies Limited as an individual company and do not contain consolidated financial information as the parent of a group. The company has taken the option under Section 398 of the Companies Act 2006 not to prepare consolidated financial statements.

Going concern

The financial statements have been prepared on the going concern basis. The directors consider this appropriate as the company is supported by the value of its licences and it continues to meet its day to day commitments from working capital and existing financial arrangements as they fall due. The directors are confident that the company has adequate resources to continue in operational existence for the foreseeable future and remain committed to funding capital commitments from personal funds if required.

Turnover

Turnover represents the total value, excluding VAT, of revenue earned during the period from the sale of pharmaceutical products.

Government grants

Grants that are received in respect of expenditure incurred by the entity are recognised in profit and loss in the period when the grant becomes receivable.

Licences

Licences represent fees paid to obtain permission to operate pharmacies and are being amortised evenly over their estimated lives of 20 years. This is a departure from the requirements of section 1A of FRS 102 which requires intangible assets to be amortised over a period not exceeding 10 years. The directors believe the company's licences have a lifespan longer than 10 years and consider 20 years is a more accurate period for amortisation of the licences.

If the licences had been amortised over 10 years the amortisation charge to the profit and loss account would have been £77,397 (2024 £77,397), resulting in a decrease in the profit of £38,699 (2024 £38,699).

Tangible assets

Tangible fixed assets are stated at historical cost less accumulated depreciation and accumulated impairment losses.

 

Wellbeing Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

Depreciation

Depreciation is provided at rates calculated so as to write off the cost less residual value of each asset over its expected useful life as follows:

Asset class

Depreciation method and rate

Plant and equipment

10% per annum straight line

Fixtures and fittings

10% per annum straight line

Office equipment

20% per annum straight line

Tenants' improvements

5% per annum straight line

Motor vehicles

25% per annum straight line

Impairment of assets

At each reporting date fixed assets are reviewed to determine whether there is any indication that those assets have suffered an impairment loss. If there is an indication of possible impairment, the recoverable amount of any affected asset is estimated and compared with its carrying amount. If the estimated recoverable amount is lower, the carrying amount is reduced to its estimated recoverable amount, and an impairment loss is recognised immediately in profit or loss.
If an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but not in excess of the amount that would have been determined had no impairment loss been recognised for the asset in prior years. A reversal of an impairment loss is recognised immediately in profit or loss.

Investments in associates

Investments in associated companies are recognised at cost less impairment. Gains or losses on disposal of these investments are recognised in the profit and loss account.

Stock

Stock is stated at the lower of cost and net realisable value, and comprises pharmaceutical products for resale.

Tax

Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and loss account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Group relief
Tax losses surrendered to any group company are paid in full by the claimant company.

Debtors

Trade debtors are amounts due for products sold in the ordinary course of business.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

 

Wellbeing Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

Leases

Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. The Capital element of the future payments is treated as a liability. The interest element of these obligations is charged to the profit and loss account over the relevant period on a straight line basis. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is shorter.

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs

The company operates defined contribution pension schemes for the benefit of its employees and one of its directors. Contributions payable to the pension schemes are charged to the profit and loss account in the period to which they relate and their assets are held separately from those of the company.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 32 (2024 - 35).

4

Other operating income

2025

2024

£

£

Management charges receivable

42,000

121,563

Gain on disposal of fixed asset investments (2024 tangible fixed assets)

58,525

1,870

Other operating income

3,746

3,628

104,271

127,061

5

Taxation

The tax charge / (credit) on the profit/loss for the year was as follows:

2025

2024

£

£

Corporation tax charge

40,624

-

Deferred tax

5,480

22,165

46,104

22,165

6

Licences

Licences
 £

Total
£

Cost

At 1 January 2025

773,971

773,971

At 31 December 2025

773,971

773,971

Amortisation

At 1 January 2025

128,021

128,021

Amortisation charge

38,699

38,699

At 31 December 2025

166,720

166,720

Carrying amount

At 31 December 2025

607,251

607,251

At 31 December 2024

645,950

645,950

 

Wellbeing Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

7

Tangible assets

Leasehold improvements
£

Furniture, fittings and equipment
 £

Total
£

Cost

At 1 January 2025

12,069

335,732

347,801

Additions

-

9,945

9,945

At 31 December 2025

12,069

345,677

357,746

Depreciation

At 1 January 2025

5,821

195,701

201,522

Charge for the year

604

20,091

20,695

At 31 December 2025

6,425

215,792

222,217

Carrying amount

At 31 December 2025

5,644

129,885

135,529

At 31 December 2024

6,248

140,031

146,279

Included within furniture, fittings and equipment are assets purchased on hire purchase contracts with a net book value of £45,466 (2024 £51,394).

 

Wellbeing Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

8

Investments

2025
£

2024
£

Investments in associates

187,074

222,299

Associates

£

Cost

At 1 January 2025

222,299

Disposals

(35,225)

At 31 December 2025

187,074

Provision

Carrying amount

At 31 December 2025

187,074

At 31 December 2024

222,299

Investments in associates comprise: Wellbeing Rushport (Middlewich) Limited £100,100 (2024 - £100,100); Abbey Field Health Limited £86,924 (2024 - £86,924); Wellbeing (Keynsham) Limited £50 (2024 - £50); and Wellbeing Rushport (Whitton) Limited £0 (2024 - £35,225).

Wellbeing Pharmacies Limited has a 50% interest in Wellbeing Rushport (Middlewich) Limited and a 19% interest in Abbey Field Health Limited. During the year the company sold its 50% shareholding in Wellbeing Rushport (Whitton) Limited and since the year end has sold its 50% shareholding in Wellbeing Rushport (Middlewich) Limited.

9

Debtors

Current

Note

2025
£

2024
£

Trade debtors

16

295,225

265,981

Amounts owed by related parties

 

50,000

50,000

Prepayments

 

15,426

32,450

Other debtors

 

66,716

79,241

   

427,367

427,672

Included in debtors are balances due from related parties, which are included at note 16. Additionally the balance of £50,000 (2024 £50,000) above represents other funds due from related company Wellbeing Rushport (Middlewich) Limited.

 

Wellbeing Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

10

Creditors

Creditors: amounts falling due within one year

Note

2025
£

2024
£

Due within one year

 

Loans and borrowings

12

41,350

46,941

Trade creditors

 

666,187

712,028

Taxation and social security

 

58,895

16,121

Accruals and deferred income

 

13,607

10,562

Other creditors

 

109,966

126,706

 

890,005

912,358

Creditors: amounts falling due after more than one year

Note

2025
£

2024
£

Due after one year

 

Loans and borrowings

12

601,912

643,660


Other creditors include loans of £100,000 (2024 £100,000) from directors which are interest free and have no repayment terms.

Creditors also include balances due to other related parties. Details of related party transactions are disclosed at note 16.

11

Provisions for liabilities

2025

2024

£

£

Deferred tax: accelerated capital allowances

27,645

22,165

Deferred tax

Balance at 1 January 2025

22,165

Charge / (credit) to P&L during the year

5,480

Balance at 31 December 2025

27,645

 

Wellbeing Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

12

Loans and borrowings

Non-current loans and borrowings

2025
£

2024
£

Bank borrowings

580,972

610,916

Hire purchase contracts

20,940

32,744

601,912

643,660

Current loans and borrowings

2025
£

2024
£

Bank borrowings

29,546

35,137

Hire purchase contracts

11,804

11,804

41,350

46,941

In September 2023 the company borrowed £659,750 from Santander UK plc in order to purchase another pharmacy. The loan bears interest at 2.95% per annum above base rate and its repayment date is September 2029. The company also entered into an overdraft agreement with Sandander UK plc in 2023.

The company has provided securities by way of a fixed charge and a bond and floating charge over its property and undertakings in favour of Santander UK plc in support of its and its holding company's borrowings.

In 2020 the company borrowed £50,000 through the government's bounce back loan scheme, made available to businesses in response to the coronavirus pandemic. The loan is interest free for the first 12 months (the first 12 months interest was paid by the UK Government) and no repayments were due within this period. Interest is then charged at 2.5% per annum and the loan is repayable over the following 5 years by monthly instalment.

13

Share capital

Allotted, called up and fully paid shares

 

2025

2024

 

No.

£

No.

£

Ordinary of £0.10 each

58,823

5,882

58,823

5,882

         

14

Dividends

Interim dividends paid

2025
£

2024
£

Interim dividend of £3.88 (2024 - £4.80) per each Ordinary share

228,233

282,350

 

 
 

Wellbeing Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

15

Obligations under leases

Operating Leases

The total of future minimum lease payments are as follows:

2025

2024

£

£

Not later than one year

83,788

76,550

Later than one year and not later than five years

332,819

299,785

Later than five years

1,031,807

1,021,919

1,448,414

1,398,254

16

Related party transactions

Wellbeing Healthcare Holdings Limited was incorporated on 18 May 2022 and acquired the entire shareholding of Wellbeing Pharmacies Limited on 31 October 2022. Its shareholders are Mr M A Hedley, Mrs J A Hedley, Mr F T Gourlay & Mr K A Murphy. Messrs Hedley, Gourlay and Murphy are also directors of this company and remain directors of Wellbeing Pharmacies Limited.

Mr M A Hedley is also:
- a director and shareholder of MAF Pharma Limited, a pharmaceutical wholesaler;
- a director of Wellbeing (Keynsham) Limited, Wellbeing Rushport (Middlewich) Limited** and Wellbeing Rushport (Whitton) Limited*, all retail pharmacies; and
- a director and shareholder of MAH Consulting Limited, providing consultancy services principally to the pharmacy and wholesale pharmaceutical sectors.

Mr F T Gourlay is also a director and shareholder of MAF Pharma Limited; and a director of Wellbeing (Keynsham) Limited, Wellbeing Rushport (Whitton) Limited*, Wellbeing Rushport (Middlewich) Limited** and Abbey Field Health Limited.

Mr K A Murphy is also a director of Wellbeing Rushport (Middlewich) Limited**.

*Wellbeing Rushport (Whitton) Limited was sold in January 2025.
**Wellbeing Rushport (Middlewich) Limited was sold in March 2026.

 

Wellbeing Pharmacies Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2025 (continued)

The following related party transactions took place at arms' length during the year:

Goods and services provided by

Goods and services purchased by

Wellbeing Pharmacies Limited

Wellbeing Pharmacies Limited

2025

2024

2025

2024

£

£

£

£

Abbey Field Health Limited

49,341

48,173

-

-

MAF Pharma Limited

463

-

80,814

110,188

MAH Consulting Limited

-

-

13,000

6,000

Medicine Collection Limited

-

20,123

-

-

Wellbeing (Keynsham) Limited

111

53,350

-

-

Wellbeing Rushport (Middlewich) Limited

21,807

19,074

376

-

Wellbeing Rushport (Whitton) Limited

1,845

24,860

-

-

73,567

165,580

94,190

116,188

At the year end the following balances (excluding investments) were due:

Debtor balances: due to

Creditor balances: due from

Wellbeing Pharmacies Limited

Wellbeing Pharmacies Limited

2025

2024

2025

2024

£

£

£

£

Abbey Field Health Limited

1,477

6,981

-

-

MAF Pharma Limited

-

16,000

133,800

187,566

MAH Consulting Limited

-

-

-

7,200

Wellbeing (Keynsham) Limited

-

124

-

-

Wellbeing Rushport (Middlewich) Limited

1,119

665

-

-

Wellbeing Rushport (Whitton) Limited

-

472

-

-

2,596

24,242

133,800

194,766

At the year end loans due to directors were as follows:

2025

2024

Interest:

Repayment terms:

£

£

Mr M A Hedley

no interest

no fixed repayment terms

25,000

25,000

Mr F T Gourlay

no interest

no fixed repayment terms

25,000

25,000

Mr G P Rowley *

no interest

no fixed repayment terms

25,000

25,000

Mr K A Murphy

no interest

no fixed repayment terms

25,000

25,000

100,000

100,000

* Mr G P Rowley resigned as director in September 2022.